A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Table 1 CAIA model joint inflammation histopathology scores^a

Group	Proteoglycan loss	Matrix erosion	Subchondral osteolysis	Osteoproliferation	Synovial proliferation	Pannus formation	Inflammation degree
Vehicle	1.55 ± 0.07	3.12 ± 0.71	2.50 ± 1.00	1.65 ± 0.47	2.00 ± 0.81	1.12 ± 0.85	1.75 ± 0.95
CEP-33779 10 mg/kg	1.39 ± 0.38	3.40 ± 2.07	2.30 ± 1.30	1.70 ± 1.09	2.40 ± 1.34	1.30 ± 0.97	1.60 ± 1.14
CEP-33779 30 mg/kg	1.12 ± 0.88	0.75 ± 0.95	0.62 ± 0.47*	0.87 ± 0.62	0.25 ± 0.50*	0.00 ± 0.00	0.12 ± 0.25*
CEP-33779 55 mg/kg	2.05 ± 0.07	0.70 ± 0.44*	0.60 ± 0.41**	0.30 ± 0.72*	0.30 ± 0.44*	0.00 ± 0.00*	0.20 ± 0.27*
Dex 1.5 mg/kg	0.98 ± 0.44	1.00 ± 0.79	0.50 ± 0.35**	0.70 ± 0.44	0.40 ± 0.54*	0.10 ± 0.22	0.30 ± 0.44*
Compared to vehicle	*P < 0.05	**P < 0.01	***P < 0.001

^aCAIA, collagen-antibody induced arthritis; Dex, dexamethasone. Hematoxylin and eosin- and Safranin O-stained, paraffin wax-embedded carpus and tarsus sections were scored by a board-certified independent pathologist for the criteria described in Materials and methods. Values are means ± SD for the tarsus only. P values show significance as compared to vehicle group; n = 5 mice per group. Statistical test used was two-way analysis of variance (ANOVA). *P < 0.05. **P < 0.01. ***P < 0.001.

ISSN: 1478-6362